Form 4: Century Therapeutics Executive Granted Stock Options and Restricted Stock Units

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, received stock options and restricted stock units (RSUs) according to a recent SEC Form 4 filing.

Summary

• Gregory Russotti, Chief Technology and Manufacturing Officer at Century Therapeutics, was granted 146,000 stock options with an exercise price of $5.32 on March 7, 2024.
• These options vest 25% on March 7, 2025, and the remaining 75% vest in 36 equal monthly installments.
• Russotti also received 24,000 restricted stock units (RSUs) on the same date.
• These RSUs vest 25% on March 7, 2025, with the remaining 75% vesting quarterly over the following three years.
• Each RSU represents a contingent right to receive one share of Century Therapeutics common stock.
• Following these transactions, Russotti directly owns 302,319 shares of Century Therapeutics common stock and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.
• The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934.
• Douglas Carr, acting as Attorney-in-Fact, signed the filing on behalf of Gregory Russotti on March 11, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and RSUs is a standard practice and suggests confidence in the executive's future contributions. There are no explicitly negative aspects presented in the filing.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The vesting schedules for the stock options and RSUs indicate a multi-year commitment from the executive to the company.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, vary significantly across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Century Therapeutics' executive compensation to that of similar-sized companies in the cell therapy space (e.g., Allogene Therapeutics, CRISPR Therapeutics) would provide a more detailed benchmark.
• Typical vesting schedules for stock options and RSUs in the biotech industry range from three to five years, with some companies offering accelerated vesting upon certain events such as a change in control.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with long-term value creation.
• Employees may be motivated by the fact that executives are incentivized to improve company performance.

Key Dates